| Identification | Back Directory | [Name]
MK-0773 | [CAS]
606101-58-0 | [Synonyms]
MK-0773
PF05314882
PF-05314882
PF 05314882
MK0773;MK 0773;PF 05314882;PF-05314882;PF05314882
N-(3H-Imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
1H-Indeno[5,4-f]quinoline-7-carboxamide, 3-fluoro-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-1,4a,6a-trimethyl-2-oxo-, (4aS,4bS,6aS,7S,9aS,9bS,11aR)- | [Molecular Formula]
C27H34FN5O2 | [MDL Number]
MFCD18251586 | [MOL File]
606101-58-0.mol | [Molecular Weight]
479.59 |
| Chemical Properties | Back Directory | [Boiling point ]
754.2±60.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 33.33 mg/mL (69.50 mM; Need ultrasonic) | [form ]
Powder | [pka]
10.29±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues. Furthermore, MK-0773 is useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal | [target]
androgen receptor | [storage]
Store at -20°C |
|
|